Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Intangibles (2023 - 2024)

Historic Intangibles for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $10.4 million.

  • BioLineRx's Intangibles fell 2157.63% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year decrease of 2157.63%. This contributed to the annual value of $10.4 million for FY2024, which is 2965.53% down from last year.
  • Per BioLineRx's latest filing, its Intangibles stood at $10.4 million for Q3 2025, which was down 2157.63% from $10.4 million recorded in Q2 2025.
  • Over the past 5 years, BioLineRx's Intangibles peaked at $22.0 million during Q3 2023, and registered a low of $10.4 million during Q3 2025.
  • In the last 3 years, BioLineRx's Intangibles had a median value of $13.7 million in 2024 and averaged $14.9 million.
  • In the last 5 years, BioLineRx's Intangibles tumbled by 3986.47% in 2024 and then tumbled by 2157.63% in 2025.
  • BioLineRx's Intangibles (Quarter) stood at $14.9 million in 2023, then fell by 29.66% to $10.4 million in 2024, then dropped by 0.58% to $10.4 million in 2025.
  • Its Intangibles was $10.4 million in Q3 2025, compared to $10.4 million in Q2 2025 and $10.4 million in Q1 2025.